
https://www.science.org/content/blog-post/yuri-milner-s-millions-and-they-re-going
# Article Title (March 2013)

## 1. SUMMARY

The article discusses Yuri Milner's establishment of the Breakthrough Prize in Life Sciences in 2013, awarding $3 million each to 11 university-based biologists. The author notes that nearly all winners were involved in cancer genetics or cancer stem cell research, suggesting these fields were becoming central to cancer cure research due to advances in DNA sequencing and stem cell understanding. The piece speculates about whether billionaires like Milner have personal stakes in such funding, compares this to other tech billionaires' unconventional investments (Musk, Bezos, Brin), and questions why relatively little tech-era money had flowed into biopharma venture capital. The author suggests that funding basic science might offer better returns than commercial ventures at this stage of biomedical research.

## 2. HISTORY

The Breakthrough Prize in Life Sciences has continued as an annual award since 2013, substantially elevating its recipients' profiles and providing significant research funding. The prizes have recognized numerous foundational discoveries that later translated into clinical impact, including cancer immunotherapy (James Allison, 2014), CRISPR gene editing (Emmanuelle Charpentier, Jennifer Doudna, 2015), and RNA biology. By 2023, the prize had distributed over $300 million to more than 50 scientists.

Cancer genetics and stem cell research have indeed produced significant results since 2013. CAR-T cell therapies received FDA approval starting in 2017 (Kymriah, Yescarta), demonstrating the clinical viability of immune cell engineering for blood cancers. Checkpoint inhibitor drugs (Keytruda, Opdivo) became blockbuster therapies, validating the cancer immunotherapy approach. Liquid biopsies for cancer detection emerged commercially, though widespread clinical adoption remains ongoing. Cancer genomics has become standard in treatment protocols for many cancers.

However, cancer stem cell research has had mixed translational success. While the concept has advanced scientific understanding, relatively few therapies specifically targeting cancer stem cells have reached the clinic successfully. The field has proven more complex than initially hoped, with challenges in identifying and targeting true cancer stem cells across tumor types.

The pharmaceutical venture capital landscape has evolved. Since 2013, substantial tech capital has entered biopharma through entities like Andreessen Horowitz Bio + Health, Alphabet's life sciences ventures (Verily, Calico), and increased funding for computational drug discovery platforms. The biotech IPO market experienced cycles of boom and bust, with the 2020-2021 period seeing unprecedented funding levels.

## 3. PREDICTIONS

The article did not make explicit predictions, but contained several implicit assumptions about future developments:

• **Cancer genetics and stem cell research would yield major clinical advances**: 
  - Partially accurate: Cancer genetics has powerfully influenced treatment (molecular profiling, targeted therapies). Cancer stem cell targeting has been less clinically successful than hoped, with more modest therapeutic impact.

• **Tech billionaires would increasingly fund biomedical research**: ✓ Correct
  - This trend intensified dramatically. Beyond Milner's prizes, major initiatives emerged: Bezos's Altos Labs (cellular rejuvenation, $3B+), Thiel's longevity research funding, Gates Foundation's continued biotech investments, and numerous tech entrepreneurs founding or backing biotech companies.

• **Academic funding might prove more efficient than venture capital for early research**: ✓ Largely correct
  - The NIH budget grew significantly, and academic discoveries continued driving biotech innovation. Many breakthrough therapies originated in academic labs (CAR-T: University of Pennsylvania; CRISPR: Berkeley/Broad Institute).

## 4. INTEREST

Rating: **7/10**

The article identified a significant trend in scientific funding and highlighted the growing intersection of technology wealth with biomedical research, correctly anticipating the increasing importance of cancer genetics research. It captured an important moment in the evolution of scientific philanthropy, though the broader clinical picture remained incompletely understood.

---


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20130301-yuri-milner-s-millions-and-they-re-going.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_